Developed in collaboration with Janssen and Mayo Clinic, this technology has the potential to aid physicians in earlier detection of pulmonary hypertension, a progressive, life-threatening disease

CAMBRIDGE, Mass. – March 28, 2026 – Anumana, a leader in cardiovascular AI, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its pulmonary hypertension (PH) algorithm, an AI-enabled…

Award recognizes Anumana’s innovative AI-driven cardiovascular disease detection technology

#TeamAnumana wrapped up three incredible days of exploring cardiovascular science in the Windy City at the American College of Cardiology’s Annual Scientific Session. ACC.25 brought together thousands of cardiologists, investigators,…